JAPAN DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

JAPAN DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Japan Diabetes Drugs Market is expected to register a CAGR of more than 3% over the forecast period (2022-2027).

The COVID-19 pandemic has had a substantial impact on the diabetes drugs market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of diabetes care devices. A retrospective analysis was presented at the virtual 81st Scientific Sessions of the American Diabetes Association (ADA) which showed diabetes was the main risk factor for the accelerated advancement to a severe state in Japanese COVID-19 patients.Throughout the pandemic, diabetes has persisted as a significant risk factor for COVID-19. In hospitalized patients with diabetes and COVID-19, one in 10 people died within seven days of admission.

The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes drugs, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the Japanese diabetes drugs market's growth.

While Type 1 diabetes is caused by an immune system malfunction, Type 2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. Hence, Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be characterized as insulin-dependent diabetes. Japan has one of the largest elderly populations in the world which is more susceptible to the onset of type 2 diabetes. As Japan’s population continues to age, the prevalence of diabetes increases as well. The monitoring and management of blood glucose levels are on the rise, to avoid negative consequences, such as cardiovascular diseases, kidney disorders, and many other conditions. ​

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsOral Anti-Diabetic Drugs held the largest market share in the Japan Diabetes Drugs Market in 2021

The Oral Anti-Diabetic Drugs market is expected to register a CAGR of more than 4.5% and record revenue of about USD 2.7 billion during the forecast period 2022-2027.

Oral Anti-Diabetic Drugs have been available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in the treatment of type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Antidiabetic drugs help diabetes patients to keep their condition under control and lower the risk of diabetes complications. People with diabetes may need to take antidiabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost, so they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

The prevalence of diabetes is growing among all ages in Japan, which can be attributed to the growing obese population, along with unhealthy diets and sedentary lifestyles. The prevalence of diabetes in adults is around 7% in Japan. ​Diabetes mellitus has been of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. The Japanese healthcare system has a few disease management programs conducted by the Japan Association for Diabetes Education and Care. Japan is one of the regional leaders in Asia-Pacific, in terms of diabetic public health policies. The country promotes public awareness and embraces preventive policies that focus on lifestyle and dietary adjustments, which can lessen the likelihood of adult-onset diabetes.

The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported that poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness which is likely to drive the segment growth during the forecast period.

Sodium-glucose cotransport -2 (SGLT-2) inhibitor Segment is Expected to register the highest CAGR in the Japan Diabetes Drugs Market

Sodium-glucose cotransport -2 (SGLT-2) inhibitor Segment is Expected to register a CAGR of more than 8% recording revenue of around USD 1.3 billion during the forecast period.

SGLT-2 inhibitors, commonly known as gliflozins, are a kind of medication used to treat type 2 diabetes by lowering high blood glucose levels. SGLT-2 inhibitors have an important role in the management of cardiovascular risk factors such as blood pressure, glycemia, weight, cardiac function, and anti-inflammatory action. Diabetic medications have been proposed as prospective treatments for diabetic people infected with SARS-CoV-2 during the COVID-19 epidemic.

Technological advancements have increased over the period leading to several modifications either in the SGLT-2 inhibitors or the formulations being developed. Diabetes has emerged as a global epidemic, Japan has around 11 million people with diabetes according to IDF 2021 data. Diabetes has been identified as a healthcare priority by the Ministry of Health, Labour, and Welfare (MHLW). The high prevalence of type 2 diabetes is associated with a significant economic burden.

The costs of diabetes are increased in patients with co-morbidities such as hypertension and hyperlipidemia and in patients who develop complications. Costs increase with an increasing number of complications. Well-organized medical insurance systems cover all medical fees for diabetes mellitus, and diabetics can visit doctors freely in Japan. Such advantages have helped the rise in the adoption of these products in the Japanese market.

Competitive Landscape

The Japan Diabetes Drugs Market is consolidated, with major manufacturers namely Sanofi, Novo Nordisk, and AstraZeneca holding a presence in the region. A major share of the market is held by manufacturers that are concomitant with strategy-based M&A operations and are constantly entering the market to generate new revenue streams and boost existing ones.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.